SB 567 Modifies provisions relating to health insurance
Sponsor: Dougherty Co-Sponsor(s)
LR Number: 3385L.05T Fiscal Note: 3385-05
Committee: Aging, Families, Mental & Public Health
Last Action: 7/6/2006 - Signed by Governor Journal Page:
Title: HCS SCS SBs 567 & 792 Calendar Position:
Effective Date: August 28, 2006
House Handler: Schaaf

Full Bill Text | All Actions | Available Summaries | Senate Home Page | List of 2006 Senate Bills

Current Bill Summary

HCS/SCS/SBs 567 & 792 -This act modifies laws on health insurance coverage.


Currently, an employer may provide or contract for health insurance at a reduced premium rate for employees who do not smoke or use tobacco products. This act allows the employer to also provide or contract for health insurance at a reduced deductible level for employees who do not smoke or use tobacco products. Insurers or small-employer carriers offering these policies will not be in violation of any unfair trade practice.

These provisions are similar to HB 1101 (2006).


This act requires health insurance companies to provide coverage for routine patient care costs incurred as the result of phase II clinical trials undertaken to treat cancer. Currently, Section 376.429, RSMo, requires coverage for phases III or IV only. In addition, health benefit plans may limit coverage for the routine patient care costs of patients in phase II of a clinical trial to those treating facilities within the health benefit plans' provider network; except that, this provision shall not be construed as relieving a health benefit plan of the sufficiency of network requirements under state statute.

Routine patient care costs coverage for phase II clinical trials shall apply if the trial is sanctioned by the National Institutes of Health (NIH) or National Cancer Institute (NCI) and conducted at an academic or National Cancer Institute Center; and the person covered under this section is enrolled in the clinical trial and not merely following the protocol of phase II clinical trials. In addition, the provisions of this act regarding phase II of a clinical trial shall not apply automatically to an individually underwritten health benefit plan, but shall be an option to any such plan.


This act provides that health insurers will be required to charge only one co-payment on a prescription if the required single dosage is not available and a combination of dosage amounts must be dispensed to fill the prescription. This provision does not apply to prescriptions in excess of a one-month supply. If technology does not permit adjudication, the health carrier or health benefit plan will provide reimbursement forms for the patients.

These provisions are similar to HB 1904 (2006).